Harnessing the synergistic potential of biologically targeted therapies in cutaneous T-cell lymphoma

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Associate Professor of Dermatology and Director of the Comprehensive Skin Cancer Center, Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.

Comment

Christina Chung Patrone et al. Oncotarget. 2019.

. 2019 Mar 8;10(20):1860-1861.

doi: 10.18632/oncotarget.26751.

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Associate Professor of Dermatology and Director of the Comprehensive Skin Cancer Center, Department of Dermatology, Columbia University Irving Medical Center, New York, NY, USA.

No abstract available

Keywords: BET inhibitor; CTCL; cutaneous T cell lymphoma; histone deacetylase; romidepsin.

Comment on

BET inhibition in advanced cutaneous T cell lymphoma is synergistically potentiated by BCL2 inhibition or HDAC inhibition.
Kim SR, Lewis JM, Cyrenne BM, Monico PF, Mirza FN, Carlson KR, Foss FM, Girardi M. Kim SR, et al. Oncotarget. 2018 Jun 26;9(49):29193-29207. doi: 10.18632/oncotarget.25670. eCollection 2018 Jun 26. Oncotarget. 2018. PMID: 30018745 Free PMC article.

1. Chang LW, et al. J Invest Dermatol. 2018;138:2681–83. doi: 10.1016/j.jid.2018.06.176. - DOI - PubMed
1. Patrone CC, et al. Journal of Investigative Dermatology. 2018;138:S33. doi: 10.1016/j.jid.2018.03.197. - DOI
1. Cosenza M, et al. Cancer Biol Ther. 2016:1–13. doi: 10.1080/15384047.2016.1219820. - DOI - PMC - PubMed
1. Heider U, et al. Eur J Haematol. 2009;82:440–9. doi: 10.1111/j.1600-0609.2009.01239.x. - DOI - PubMed
1. Cyrenne BM, et al. Blood. 2017;130:2073–83. doi: 10.1182/blood-2017-06-792150. - DOI - PMC - PubMed